93 related articles for article (PubMed ID: 11170058)
1. Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells.
Goto T; Nakano T; Kohno T; Morimatsu S; Morita C; Hong W; Kiso Y; Nakai M; Sano K
J Med Virol; 2001 Mar; 63(3):203-9. PubMed ID: 11170058
[TBL] [Abstract][Full Text] [Related]
2. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
Humphrey RW; Ohagen A; Davis DA; Fukazawa T; Hayashi H; Höglund S; Mitsuya H; Yarchoan R
Antimicrob Agents Chemother; 1997 May; 41(5):1017-23. PubMed ID: 9145862
[TBL] [Abstract][Full Text] [Related]
3. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
Kageyama S; Mimoto T; Murakawa Y; Nomizu M; Ford H; Shirasaka T; Gulnik S; Erickson J; Takada K; Hayashi H
Antimicrob Agents Chemother; 1993 Apr; 37(4):810-7. PubMed ID: 8494379
[TBL] [Abstract][Full Text] [Related]
4. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
Uchida H; Maeda Y; Mitsuya H
Antiviral Res; 1997 Nov; 36(2):107-13. PubMed ID: 9443667
[TBL] [Abstract][Full Text] [Related]
6. Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.
Martinez ZS; Castro E; Seong CS; Cerón MR; Echegoyen L; Llano M
Antimicrob Agents Chemother; 2016 Oct; 60(10):5731-41. PubMed ID: 27431232
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
[TBL] [Abstract][Full Text] [Related]
9. Fusion of uninfected T-cells occurs with immature HIV-1 protease-mutant, but not morphologically similar protease inhibitor derived particles.
Bahmani MK; Kameoka M; Goto T; Sano K; Luftig RB; Ikuta K
Virus Res; 2000 Feb; 66(2):131-7. PubMed ID: 10725546
[TBL] [Abstract][Full Text] [Related]
10. Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor.
Schätzl H; Gelderblom HR; Nitschko H; von der Helm K
Arch Virol; 1991; 120(1-2):71-81. PubMed ID: 1929879
[TBL] [Abstract][Full Text] [Related]
11. Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages.
Davis DA; Read-Connole E; Pearson K; Fales HM; Newcomb FM; Moskovitz J; Yarchoan R
Antimicrob Agents Chemother; 2002 Feb; 46(2):402-8. PubMed ID: 11796349
[TBL] [Abstract][Full Text] [Related]
12. Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation.
Babé LM; Craik CS
Antimicrob Agents Chemother; 1994 Oct; 38(10):2430-9. PubMed ID: 7840583
[TBL] [Abstract][Full Text] [Related]
13. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
Chokekijchai S; Shirasaka T; Weinstein JN; Mitsuya H
Antiviral Res; 1995 Sep; 28(1):25-38. PubMed ID: 8585758
[TBL] [Abstract][Full Text] [Related]
14. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.
Mimoto T; Imai J; Kisanuki S; Enomoto H; Hattori N; Akaji K; Kiso Y
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2251-3. PubMed ID: 1423795
[TBL] [Abstract][Full Text] [Related]
15. Effect of a human immunodeficiency virus protease inhibitor on human monocyte function.
Bugelski PJ; Kaplan JM; Hart TK; Miller J; Laydon JT; Lee JC; Dreyer GB; Kirsh R
AIDS Res Hum Retroviruses; 1992 Dec; 8(12):1951-8. PubMed ID: 1493045
[TBL] [Abstract][Full Text] [Related]
16. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins.
Kageyama S; Anderson BD; Hoesterey BL; Hayashi H; Kiso Y; Flora KP; Mitsuya H
Antimicrob Agents Chemother; 1994 May; 38(5):1107-11. PubMed ID: 8067746
[TBL] [Abstract][Full Text] [Related]
17. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.
Ashorn P; McQuade TJ; Thaisrivongs S; Tomasselli AG; Tarpley WG; Moss B
Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7472-6. PubMed ID: 2217178
[TBL] [Abstract][Full Text] [Related]
18. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
McQuade TJ; Tomasselli AG; Liu L; Karacostas V; Moss B; Sawyer TK; Heinrikson RL; Tarpley WG
Science; 1990 Jan; 247(4941):454-6. PubMed ID: 2405486
[TBL] [Abstract][Full Text] [Related]
19. DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein.
Rayner MM; Cordova BC; Meade RP; Aldrich PE; Jadhav PK; Ru Y; Lam PY
Antimicrob Agents Chemother; 1994 Jul; 38(7):1635-40. PubMed ID: 7979297
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV-1 Maturation via Small-Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein.
Wang W; Zhou J; Halambage UD; Jurado KA; Jamin AV; Wang Y; Engelman AN; Aiken C
J Virol; 2017 May; 91(9):. PubMed ID: 28202766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
